immatics Biotechnologies GmbH (immatics)

Oncology Corporate Profile

Company Description

immatics biotechnologies is an independent biopharmaceutical company dedicated to the rational development of novel active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. immatics has currently three products ' IMA901 for the therapy of renal cell cancer, IMA910 for the treatment of colon cancer and IMA950 for the treatment of glioma ' under clinical investigation in international studies up to phase 3.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IMA901tumor associated peptide (TUMAP)Renal cell carcinoma (RCC)III
IMA910tumor associated peptide (TUMAP)Colorectal cancerII
IMA950tumor associated peptide (TUMAP)GliomaI
IMA942tumor associated peptide (TUMAP)Gastric cancerPreclinical
IMA930tumor associated peptide (TUMAP)Non Small Cell Lung Cancer (NSCLC)PreclinicalRoche
IMA962tumor associated peptide (TUMAP)Prostate cancerPreclinicalRoche

View additional information on product candidates here »


Recent News Headlines

There are no news items to display